Leading causes of castration-resistant prostate cancer

被引：0

作者：

Lu, Mingqian ^{[1
,2
,3
]}

Lu, Hongda ^{[4
,5
]}

Kong, Qingzhi ^{[4
,5
]}

机构：

[1] Hubei Univ Chinese Med, Clin Med Coll, Wuhan 430061, Hubei Province, Peoples R China

[2] China Three Gorges Univ, Dept Oncol, Yichang 443003, Hubei Province, Peoples R China

[3] Yichang Cent Peoples Hosp, Dept Oncol, Yichang 443003, Hubei Province, Peoples R China

[4] Cent Hosp Wuhan, Dept Oncol, Wuhan 430014, Hubei Province, Peoples R China

[5] Canc Res Inst Wuhan, Wuhan 430014, Hubei Province, Peoples R China

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 04期

基金：

湖北省教育厅重点项目;

关键词：

androgen receptor; androgen receptor mutation; androgen receptor splicing; castration-resistant prostate cancer; neuroendocrine; progenitor cells; ANDROGEN RECEPTOR GENE; EPIDERMAL-GROWTH-FACTOR; ANTIANDROGEN WITHDRAWAL SYNDROME; TRANSGENIC MOUSE MODEL; TUMOR-CELL LINES; NEUROENDOCRINE DIFFERENTIATION; STEM-CELLS; SPLICE VARIANTS; FULL-LENGTH; CASODEX BICALUTAMIDE;

D O I：

10.1586/14737140.2015.1007957

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Androgen receptor has a key role in the initiation and progression of PCa. Currently, androgen deprivation therapy is the standard treatment for PCa patients due to its effective suppression of androgen receptor signaling. Even though androgen deprivation therapy shows its initial effectiveness on shrinking tumor size, it eventually fails to cure advanced PCa, which is determined by the occurrence of castration-resistance. In this review, we summarize the widely accepted mechanisms that account for castration-resistant PCa and discuss potential therapeutic targets.

引用

页码：425 / 432

页数：8

共 50 条

[21] Olaparib in metastatic castration-resistant Prostate Cancer
Lorenz, Judith
AKTUELLE UROLOGIE, 2022, 53 (02)
[22] Castration-Resistant Prostate Cancer: AUA Guideline
Cookson, Michael S.
Roth, Bruce J.
Dahm, Philipp
Engstrom, Christine
Freedland, Stephen J.
Hussain, Maha
Lin, Daniel W.
Lowrance, William T.
Murad, Mohammad Hassan
Oh, William K.
Penson, David F.
Kibel, Adam S.
JOURNAL OF UROLOGY, 2013, 190 (02): : 429 - 438
[23] Enzalutamide in Castration-Resistant Prostate Cancer Reply
Hussain, Maha
Saad, Fred
Sternberg, Cora N.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (14): : 1381 - 1381
[24] Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J.
Mateo, J.
Fizazi, K.
Saad, F.
Shore, N.
Sandhu, S.
Chi, K. N.
Sartor, O.
Agarwal, N.
Olmos, D.
Thiery-Vuillemin, A.
Twardowski, P.
Mehra, N.
Goessl, C.
Kang, J.
Burgents, J.
Wu, W.
Kohlmann, A.
Adelman, C. A.
Hussain, M.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22): : 2091 - 2102
[25] Advances in metastatic castration-resistant prostate cancer
Kentepozidis, Nikolaos
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S108 - S108
[26] Predicting the future in castration-resistant prostate cancer
Verhagen, Paul
LANCET ONCOLOGY, 2009, 10 (03): : 201 - 202
[27] Cabazitaxel for the treatment of castration-resistant prostate cancer
Agarwal, Neeraj
Sonpavde, Guru
Sartor, Oliver
FUTURE ONCOLOGY, 2011, 7 (01) : 15 - 24
[28] Novel treatments for castration-resistant prostate cancer
Sternberg, Cora N.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S195 - S199
[29] Visceral Disease in Castration-resistant Prostate Cancer
Pezaro, Carmel J.
Omlin, Aurelius
Lorente, David
Rodrigues, Daniel Nava
Ferraldeschi, Roberta
Bianchini, Diletta
Mukherji, Deborah
Riisnaes, Ruth
Altavilla, Amelia
Crespo, Mateus
Tunariu, Nina
de Bono, Johann S.
Attard, Gerhardt
EUROPEAN UROLOGY, 2014, 65 (02) : 270 - 273
[30] Pathophysiology and therapy of castration-resistant prostate cancer
Merseburger, A. S.
Kuczyk, M. A.
Wolff, J. M.
UROLOGE, 2013, 52 (02): : 219 - 225

← 1 2 3 4 5 →